Class information for:
Level 1: RANIBIZUMAB//INTRAVITREAL INJECTION//PEGAPTANIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2864 2053 31.7 84%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
63 28284 OPHTHALMOLOGY//RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES//AGE RELATED MACULAR DEGENERATION

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RANIBIZUMAB Author keyword 201 46% 16% 325
2 INTRAVITREAL INJECTION Author keyword 63 33% 8% 157
3 PEGAPTANIB Author keyword 61 60% 3% 67
4 AGE RELATED MACULAR DEGENERATION Author keyword 53 13% 19% 380
5 BEVACIZUMAB Author keyword 47 11% 19% 397
6 NEOVASCULAR GLAUCOMA Author keyword 36 41% 3% 69
7 ANTI VEGF Author keyword 36 33% 4% 90
8 CHOROIDAL NEOVASCULARIZATION Author keyword 33 17% 9% 175
9 LUCENTIS Author keyword 30 53% 2% 40
10 AFLIBERCEPT Author keyword 29 39% 3% 58

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 RANIBIZUMAB 201 46% 16% 325 Search RANIBIZUMAB Search RANIBIZUMAB
2 INTRAVITREAL INJECTION 63 33% 8% 157 Search INTRAVITREAL+INJECTION Search INTRAVITREAL+INJECTION
3 PEGAPTANIB 61 60% 3% 67 Search PEGAPTANIB Search PEGAPTANIB
4 AGE RELATED MACULAR DEGENERATION 53 13% 19% 380 Search AGE+RELATED+MACULAR+DEGENERATION Search AGE+RELATED+MACULAR+DEGENERATION
5 BEVACIZUMAB 47 11% 19% 397 Search BEVACIZUMAB Search BEVACIZUMAB
6 NEOVASCULAR GLAUCOMA 36 41% 3% 69 Search NEOVASCULAR+GLAUCOMA Search NEOVASCULAR+GLAUCOMA
7 ANTI VEGF 36 33% 4% 90 Search ANTI+VEGF Search ANTI+VEGF
8 CHOROIDAL NEOVASCULARIZATION 33 17% 9% 175 Search CHOROIDAL+NEOVASCULARIZATION Search CHOROIDAL+NEOVASCULARIZATION
9 LUCENTIS 30 53% 2% 40 Search LUCENTIS Search LUCENTIS
10 AFLIBERCEPT 29 39% 3% 58 Search AFLIBERCEPT Search AFLIBERCEPT

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RANIBIZUMAB 253 38% 26% 528
2 AVASTIN 113 37% 12% 243
3 IRIS NEOVASCULARIZATION 92 60% 5% 101
4 PEGAPTANIB 79 57% 5% 95
5 AVASTIN INJECTION 69 93% 1% 26
6 INTRAVITREAL BEVACIZUMAB 60 26% 10% 196
7 VERTEPORFIN PHOTODYNAMIC THERAPY 57 52% 4% 78
8 COHERENCE TOMOGRAPHY FINDINGS 56 54% 4% 72
9 VERTEPORFIN 53 20% 11% 233
10 LUCENTIS 48 76% 2% 34

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis 2015 2 22 77%
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials 2010 140 56 48%
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard 2012 44 34 88%
Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration A Systematic Review 2015 2 22 41%
Emerging Therapeutic Options in Age-Related Macular Degeneration 2015 1 10 70%
Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF 2014 7 126 78%
A review of anti-VEGF agents for proliferative diabetic retinopathy 2014 8 75 65%
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease 2011 72 199 53%
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration 2009 56 40 80%
Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration 2013 14 23 83%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 VITREORETINAL CONSULTANTS 6 100% 0.2% 4
2 MED RETINA UNIT 2 28% 0.3% 7
3 AUGENABTEILUNG 2 67% 0.1% 2
4 BIOANALYT ASSAYS 2 67% 0.1% 2
5 EYE OPHTHALMOL CHINESE PLA 2 67% 0.1% 2
6 SORBONNE PARIS CITE OPHTHALMOL 2 67% 0.1% 2
7 UMR MATEIS 5510 2 67% 0.1% 2
8 VIS IPEPO 2 31% 0.2% 5
9 SECT EXPT VITREORETINAL SURG 2 23% 0.3% 7
10 DOHENY IMAGE READING 2 20% 0.4% 8

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000273797 POLYPOIDAL CHOROIDAL VASCULOPATHY//RETINAL ANGIOMATOUS PROLIFERATION//RETINAL PIGMENT EPITHELIAL TEAR
2 0.0000207995 DIABETIC MACULAR EDEMA//TRIAMCINOLONE ACETONIDE//INTRAVITREAL TRIAMCINOLONE ACETONIDE
3 0.0000202618 CHOROIDAL NEOVASCULARIZATION//PATHOLOGIC MYOPIA//MYOPIC CHOROIDAL NEOVASCULARIZATION
4 0.0000157350 CORNEAL NEOVASCULARIZATION//LIPID KERATOPATHY//HEMANGIOGENESIS
5 0.0000118872 AGE RELATED MACULAR DEGENERATION//DRUSEN//ARMS2
6 0.0000117289 BRANCH RETINAL VEIN OCCLUSION//CENTRAL RETINAL VEIN OCCLUSION//RETINAL VEIN OCCLUSION
7 0.0000114974 RETINAL THICKNESS//RETINAL THICKNESS ANALYSER//DOHENY IMAGE READING
8 0.0000065977 23 GAUGE VITRECTOMY//23 GAUGE//SUTURELESS VITRECTOMY
9 0.0000064536 DIABETIC RETINOPATHY//K GE EYE//PENN STATE RETINA GRP
10 0.0000062503 FLT 1//VEGF RECEPTORS//VEGF165B